Niagen Bioscience (NAGE) reaffirms that the manufacturing of its Niagen ingredient and Tru Niagen and pharmaceutical-grade Niagen(R) products remain resilient amid the recently enacted global tariffs. “We made the decision to build a U.S.-based supply chain for Niagen to safeguard long-term resilience, trust, and quality,” said Rob Fried, CEO of Niagen Bioscience. “That foresight is proving valuable now. We remain confident in our ability to deliver Niagen products to customers and long-term stability to shareholders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue